Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPI-452080 in Solid Tumors
NCT05843305Phase 1Not yet recruiting
- Sponsor
- Betta Pharmaceuticals
- Start
- Apr 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BPI-452080 in solid tumor, renal cell carcinoma (RCC) and von Hippel–Lindau disease (VHL) (2 arms), sponsored by Betta Pharmaceuticals. Primary endpoint: Adverse Events. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
BPI-452080
03
Conditions
solid tumorrenal cell carcinoma (RCC)von Hippel–Lindau disease (VHL)
Beyond the preview
Go deeper on NCT05843305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05843305.